Research programme: telomerase inhibitors - Antisoma

Drug Profile

Research programme: telomerase inhibitors - Antisoma

Alternative Names: AS 1410; BRACO 19; Telomere targeting agents

Latest Information Update: 15 Mar 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cancer Research UK
  • Developer Antisoma; Cancer Research UK
  • Class
  • Mechanism of Action Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 09 Dec 2005 Antisoma has decided not to advance AS 1410 to clinical development due to unacceptable toxicity
  • 03 Jun 2005 Antisoma has signed an agreement with Heraeus so that the latter company will provide supplies of AS 1410 for clinical trials
  • 05 May 2005 Data presented at the 96th Annual Meeting of the American Association for Cancer Research (AACR-2005) have been added to the Cancer pharmacodynamics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top